Cellerant Therapeutics (Patent Portfolio of Interleukin 1 Receptor Accessory Protein) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Cellerant Therapeutics (Patent Portfolio of Interleukin 1 Receptor Accessory Protein) General Information
Description
Patent Portfolio of Interleukin 1 Receptor Accessory Protein located in The United States of America. The IL1RAP is used for cancer therapy patients that consists of stimulation of immune cells to eradicate cancer cells as well as blockade of interleukin 1 signaling.
Contact Information
Corporate Office
- 1531 Industrial Road
- San Carlos, CA 94070
- United States
Corporate Office
- 1531 Industrial Road
- San Carlos, CA 94070
- United States
Cellerant Therapeutics (Patent Portfolio of Interleukin 1 Receptor Accessory Protein) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Cellerant Therapeutics (Patent Portfolio of Interleukin 1 Receptor Accessory Protein) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Cellerant Therapeutics (Patent Portfolio of Interleukin 1 Receptor Accessory Protein) FAQs
-
Where is Cellerant Therapeutics (Patent Portfolio of Interleukin 1 Receptor Accessory Protein) headquartered?
Cellerant Therapeutics (Patent Portfolio of Interleukin 1 Receptor Accessory Protein) is headquartered in San Carlos, CA.
-
What industry is Cellerant Therapeutics (Patent Portfolio of Interleukin 1 Receptor Accessory Protein) in?
Cellerant Therapeutics (Patent Portfolio of Interleukin 1 Receptor Accessory Protein)’s primary industry is Buildings and Property.
-
Is Cellerant Therapeutics (Patent Portfolio of Interleukin 1 Receptor Accessory Protein) a private or public company?
Cellerant Therapeutics (Patent Portfolio of Interleukin 1 Receptor Accessory Protein) is a Private company.
-
What is Cellerant Therapeutics (Patent Portfolio of Interleukin 1 Receptor Accessory Protein)’s current revenue?
The current revenue for Cellerant Therapeutics (Patent Portfolio of Interleukin 1 Receptor Accessory Protein) is .
-
Who are Cellerant Therapeutics (Patent Portfolio of Interleukin 1 Receptor Accessory Protein)’s investors?
Cellerant Therapeutics has invested in Cellerant Therapeutics (Patent Portfolio of Interleukin 1 Receptor Accessory Protein).
-
When was Cellerant Therapeutics (Patent Portfolio of Interleukin 1 Receptor Accessory Protein) acquired?
Cellerant Therapeutics (Patent Portfolio of Interleukin 1 Receptor Accessory Protein) was acquired on 10-Mar-2020.
-
Who acquired Cellerant Therapeutics (Patent Portfolio of Interleukin 1 Receptor Accessory Protein)?
Cellerant Therapeutics (Patent Portfolio of Interleukin 1 Receptor Accessory Protein) was acquired by Cantargia.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process